Form 4: Maze Therapeutics Director Receives Stock Options

Nancy C Andrews, a Director at Maze Therapeutics, Inc., was granted 18,000 stock options with an exercise price of $23.67, vesting monthly over nine months starting October 1, 2025.

Summary

• Nancy C Andrews, a Director of Maze Therapeutics, Inc. (MAZE), was granted stock options.
• The transaction date for the grant was September 22, 2025.
• A total of 18,000 stock options were acquired.
• The exercise price for these options is $23.67 per share.
• The options will vest as to 1/9 of the total award monthly, with the first tranche vesting on October 1, 2025.
• Vesting is contingent upon Ms. Andrews' continued service to the Issuer.
• The options have an expiration date of September 21, 2035.
• Following this transaction, Ms. Andrews beneficially owns 18,000 derivative securities directly.

Sentiment

Score: 6

Explanation: The grant of stock options to a director is a positive for aligning management incentives with shareholder interests, but it is a routine event and does not indicate significant new positive or negative company developments.

Positives

• The grant of stock options aligns the interests of Director Nancy C Andrews with those of shareholders, incentivizing long-term company performance.
• The vesting schedule, tied to continued service, promotes retention of key board members.

Negatives

• Future exercise of these options could lead to minor dilution for existing shareholders.

Risks

• Potential future dilution of existing shareholder equity if the stock options are exercised.
• The value of the options is dependent on the future stock price exceeding the exercise price of $23.67.

Future Outlook

This filing does not contain forward-looking statements regarding the company's financial performance or strategic direction, focusing solely on an insider's equity transaction.

Industry Context

The grant of stock options to directors is a common practice in the biotechnology and pharmaceutical industries, serving as a key component of executive and board compensation packages to attract and retain talent and align their interests with long-term company success.

Stakeholder Impact

• Shareholders: Potential for minor dilution upon exercise of options; improved alignment of director incentives with shareholder value creation.

Next Steps

• The stock options will continue to vest monthly over the next nine months, subject to the director's continued service.
• The director may choose to exercise the vested options at any point before the expiration date of September 21, 2035.

Key Dates

Recommendation

This Form 4 details a routine stock option grant to a director, which is a standard compensation practice aimed at aligning interests. It does not provide new material information about the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. Investors should 'hold' and consider this as a normal course of business.

Keywords

Maze Therapeutics, MAZE, Nancy C Andrews, Stock Options, Director Compensation, SEC Form 4, Insider Transaction, Equity Grant, Vesting Schedule